🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Geert D’Haens

Amsterdam UMC Location University of Amsterdam

ORCID: 0000-0003-2784-4046

Also affiliated with Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, University of Amsterdam

Biochemistry, Genetics and Molecular BiologyMedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.4Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors

The American Journal of Gastroenterology(2020)10.14309/ajg.0000000000000596

Top 15%

1.4DataRank

Top 15%27 citations

Robert Battat, Maria Barsky, Nghia Nguyen, Christopher Ma, Neeraj Narula +11 more

Papers

Driven by 11 papers — median percentile 85. Top paper: “Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease”.

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

Gastroenterology(2020)10.1053/j.gastro.2020.01.047

N/A

5.9DataRank · unranked

318 citations

Brian G. Feagan, Edward V. Loftus, Laurent Peyrin‐Biroulet, Gert Van Assche, Geert D’Haens +17 more

Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

Gastroenterology(2020)10.1053/j.gastro.2020.03.039

N/A

5.7DataRank · unranked

240 citations

Clara Yzet, Peter Bossuyt, Filip J. Baert, Thomas Vanasek, Geert D’Haens +34 more

Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors

The American Journal of Gastroenterology(2020)10.14309/ajg.0000000000000596

Top 15%

1.4DataRank

Top 15%27 citations

Robert Battat, Maria Barsky, Nghia Nguyen, Christopher Ma, Neeraj Narula +11 more

A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice

Nature Reviews Gastroenterology & Hepatology(2024)10.1038/s41575-024-00935-y

N/A

1.4DataRank · unranked

77 citations

Mark E. Baker, Joel G. Fletcher, Vipul Jairath, Cathy Lu, Willem A. Bemelman +24 more

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data

Inflammatory Bowel Diseases(2023)10.1093/ibd/izad016

N/A

0.761DataRank · unranked

25 citations

Jacinda Tran, Geert D’Haens, David T. Rubin, Nobuo Aoyama, Wen Zhou +5 more

Disease Activity Indices for Pouchitis: A Systematic Review

Inflammatory Bowel Diseases(2021)10.1093/ibd/izab124

N/A

0.520DataRank · unranked

31 citations

Tran M Nguyen, Ahmed Almradi, Florian Rieder, Claire E. Parker, Lisa M. Shackelton +6 more

Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn’s Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies

Journal of Crohn s and Colitis(2024)10.1093/ecco-jcc/jjae164

N/A

0.303DataRank · unranked

5 citations

Marc Ferrante, Remo Panaccione, Brian G. Feagan, О. Б. Щукина, Vipul Jairath +11 more

Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn’s Disease Exhibit Similar Pharmacokinetics

Inflammatory Bowel Diseases(2023)10.1093/ibd/izad307

N/A

0.292DataRank · unranked

6 citations

S Vuijk, Ron A. A. Mathôt, Johan Van Limbergen, M Jongsma, Marco W.J. Schreurs +4 more

Crohn’s Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab

Inflammatory Bowel Diseases(2024)10.1093/ibd/izae016

N/A

0DataRank · unranked

3 citations

Toer Stevens, Bram Verstockt, David J. Gonzalez, Geert D’Haens, Parambir S. Dulai +1 more

Achieving Target Infliximab Drug Concentrations Improves Blood and Fecal Neutrophil Biomarkers in Crohn’s Disease

Inflammatory Bowel Diseases(2020)10.1093/ibd/izaa241

N/A

0DataRank · unranked

22 citations

Yi‐Ting Tsai, Kimberly Jackson, Brendan M. Boyle, Joshua D. Noe, Jeffrey S. Hyams +6 more

Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearance

Alimentary Pharmacology & Therapeutics(2022)10.1111/apt.17277

N/A

0DataRank · unranked

24 citations

Tomoyuki Mizuno, Keizo Fukushima, David Haslam, Jeffrey S. Hyams, Brendan Boyle +10 more